Jonothan C. Tierce, CPhil
With nearly 35 years of experience in health economics and outcomes research, and consulting for the healthcare industry, Mr. Tierce is a pioneer in the field of applied pharmacoeconomics, pharmacoepidemiology, and value demonstration.
Mr. Tierce is well known for providing innovative and yet practical strategies for evidence development – based on an in-depth understanding of market forces and decision-maker imperatives – for a range of clients from the public and private healthcare sectors.
With many years in the industry, as a founding leader of several HEOR business units, the path breaking ValueMedics Research, Inc., and a 3-year tenure as General Manager, Global Health Economics and Outcomes Research at IMS Consulting. Mr. Tierce has worked for dozens of clients and on hundreds of medical technologies.
He was advanced to candidacy for a Ph.D. in political science and received post-graduate training in econometrics and experimental design at the University of California, Los Angeles, where he also earned his B.A. cum laude and Masters of Arts.
E: jonothan.tierce@monumentanalytics.com
Co-Founder and Principal
Monument Analytics

Academic Affiliation
Faculty Associate, Johns Hopkins Bloomberg School of Public Health
Education
University of California, Los Angeles.
CONSULTING TEAM
Francine Chingcuanco, MHS
MANAGER
Francine Chingcuanco, MHS
Benjamin Cohen, PhD, MPH
MANAGER
Benjamin Cohen, PhD, MPH
Cullen Conway, MPH
MANAGER
Cullen Conway, MPH
Karen Dietz, MHS
MANAGER
Karen Dietz, MHS
Elena Fernandez, PharmD, PhD
MANAGER
Elena Fernandez, PharmD, PhD
Katharine Ozenberger, MS, PhDc
MANAGER
Katharine Ozenberger, MS, PhDc
Eileen Rosello, BA
SENIOR ANALYST
Eileen Rosello
Rachel Nadboy, BA
ANALYST
Rachel Nadboy
Paul Steel, MHS
ANALYST
Paul Steel, MHS
Danyang Wang, MHS
ANALYST
Danyang Wang, MHS
Ellen Hu, MHS
CONSULTANT
Ellen Hu, MHS
Divya Mohan, MHS
CONSULTANT
Divya Mohan, MHS
Jeromie Ballreich, PhD, MS
CONSULTANT
Jeromie Ballreich
Elisabeth H. Hazard, PhD
CONSULTANT
Elisabeth H. Hazard, PhD
You? Join the MA Team
WORK WITH MA
TOP TALENT?
SENIOR SCIENTIFIC ADVISORS
Daniel Touchette, PharmD, MA, FCCP
SENIOR SCIENTIFIC ADVISOR
Daniel Touchette, PharmD, MA, FCCP
Brett McQueen, PhD
SENIOR SCIENTIFIC ADVISOR
Brett McQueen, PhD
ADVISORY BOARD MEMBERS
Adrian Levy, PhD
ADVISORY BOARD MEMBER
Adrian Levy, PhD
Mark Sculpher, PhD
ADVISORY BOARD MEMBER
Mark Sculpher, PhD
Mark Sculpher is Professor of Health Economics at the Centre for Health Economics, University of York, UK where he leads the Centre’s Programme on Economic Evaluation and Health Technology Assessment. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions, a programme of research for the UK Department of Health and Social Care funded by the National Institute for Health Research (NIHR).
Mark has worked in the field of economic evaluation and health technology assessment for over 30 years. He has researched in a range of clinical areas including heart disease, cancer, diagnostics, and public health. He has also contributed to research methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty, heterogeneity and generalisability. He is also experienced in economic analysis in low income settings and is principle investigator of the Thanzi la Onse (Health for All) programme in Malawi funded by UK Research and Innovation. He has over 270 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the Economic Evaluation of Health Care Programmes (OUP, 2015 with Drummond, Claxton, Torrance and Stoddart) and Decision Modelling for Health Economic Evaluation (OUP, 2006 with Briggs and Claxton).
Mark is an emeritus member of the UK NIHR College of Senior Investigators. Hehas also been a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee and the NICE Public Health Interventions Advisory Committee. He currently sits on NICE’s Diagnostics Advisory Committee. He chaired NICE’s 2004 Task Group on methods guidance for economic evaluation and advised the Methods Working Party for the 2008 update of this guidance. Mark has advised the UK House of Commons Health and Social Care Select Committee, as well as health systems internationally on health technology assessment methods including those in France, Ireland, Japan, Singapore, Germany, Portugal, Taiwan and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme, the UK NIHR /Medical Research Council’s Methodology Research Panel and the UK Department of Health’s Policy Research Programme’s Commissioning Panel. He served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2011-12).
Rob Rayl, MBA
ADVISORY BOARD MEMBER
Rob Rayl, MBA
Rob is currently the President of R2 Medical Solutions. Rob advises small- to mid-size domestic and international companies in the biotechnology, pharmaceutical, and medical device sectors on strategy and commercial execution in the US.
With more than two decades of experience, Rob has driven multi-million-dollar revenue growth for market leading companies in Oncology, Wound Care, Pressure Injury Prevention, and Infection Control. As President, US at Molnlycke Health Care, Rob differentiated their product solutions with clinical and health economics outcomes data.
Since 2014, Rob has been on the board of Debra of America and currently serves as the Chief Development Officer (CDO) and Chief Operating Officer (COO). Debra of America is dedicated to improving the quality of life of all people living with Epidermolysis Bullosa (EB) by providing free programs and services and funding innovative research.
Rob received an Executive MBA in Leadership from the University of Georgia, Terry College of Business, a BS in Marketing Management from Valparaiso University, and a Certificate in Leadership from the University of Virginia Darden School of Business.